Amantadine
Drug-Induced Dyskinesia
Adamas Pharmaceuticals, Inc.Small moleculePhase 3Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Drug-Induced Dyskinesia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Levodopa Sumitomo Pharma Co., Ltd. | Phase 4 | A |
carbidopa AbbVie (prior sponsor, Abbott) | Phase 4 | BBB |
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)- Novartis Pharmaceuticals | Phase 2 | BBB |
Emd 128130 EMD Serono | Phase 3 | BBB |
EPA University of Stellenbosch | Phase 4 | BB |
View all 25 →
Same molecule, other indications
Amantadine is also rated in:
neurodevelopmental disorder with seizures and speech and walking impairmentDormant
BB
Indicative · Phase 3
68 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →